Lyster offers additional vaccine dose for immunocompromised

By Lyster Army Health ClinicAugust 26, 2021

Lyster Army Health Clinic, News Release:

Following the FDA’s approval of a booster dose of both the Pfizer-BioNTech and the Moderna COVID-19 vaccines for people with certain immunocompromised conditions, Lyster Army Health Clinic is now providing an additional dose of the Moderna vaccine to people with the following conditions:

•       Been receiving active cancer treatment for tumors or cancers of the blood

•       Received an organ transplant and are taking medicine to suppress the immune system

•       Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system

•       Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)

•       Advanced or untreated HIV infection

•       Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

People who are moderate to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. CDC recommends that people with moderately to severely compromised immune systems receive an additional dose of mRNA COVID-19 vaccine at least 28 days after the second dose of Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine.

Note: Lyster is only dispensing the Moderna vaccine. To limit the potential confusion surrounding the vaccine types, beneficiaries are encouraged to receive the same vaccine brand for their additional dose as they received during their initial COVID vaccinations.

Please consult with your provider if you have any questions regarding your eligibility.

Please use the DHA online appointment app to schedule your additional COVID vaccination When selecting your appointment, select the “Second Dose” option as currently the site does not have a “Third Dose” option updated on the website.

For more information about Lyster Army Health Clinic, please visit

(Photo Credit: U.S. Army) VIEW ORIGINAL